CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
Daily3h
AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion ...
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
EuropaWire9h
AstraZeneca’s Tagrisso Receives EU Recommendation as First Targeted Therapy for Unresectable EGFR-Mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
Finanznachrichten10h
Lindis Biotech GmbH: LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab
Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...
Le Lézard11h
LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab
Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...
Armed robbery in Revesby11h
Pharmanovia, Lindis Ink Deal on Catumaxomab for Ascites
Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...
Mena FN16h
Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech To Commercialise Catumaxomab For Treatment O...
Catumaxomab received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting with EU marketing authorization ...
precisionmedicineonline1d
AstraZeneca's Tagrisso Gets Nod From EMA's CHMP in Unresectable EGFR-Mutated NSCLC
If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.
Zacks.com on MSN1d
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...
GlobalData on MSN1d
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...
Business Insider1d
CHMP Recommends Approval Of Lazcluze + Rybrevant In EU For EGFR-mutated Advanced NSCLC
(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...